ProCE Banner Series

Exploring the Expanded Clinical Utility of HER2 IHC Scoring in Metastatic Breast Cancer

Key Takeaways:

  • Educate HCPs on the clinical significance of identifying patients with certain low levels of HER2 in metastatic breast cancer and raising awareness on the evolution of the HER2 spectrum
  • Highlight key considerations that impact HER2 IHC scoring and interpretation
  • Review guidance for pathologists to accurately report HER2 status

All Events

Exploring the Expanded Clinical Utility of HER2 IHC Scoring in Metastatic Breast Cancer

Past Events

April

23

2025

12:15 PM - 1:00 PM Eastern Time (ET)

Virtual

Additional Info

This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation. In adherence with PhRMA guidelines, spouses or other guests are not permitted to attend company sponsored programs. Please be advised that information such as your name and the value and purpose of any educational item, meal, or other items of value you may receive may be publicly disclosed. If you are licensed in any state or other jurisdiction, or are an employee or contractor of any organization or governmental entity that limits or prohibits meals from pharmaceutical companies, please identify yourself so that compliance with such requirements can be ensured.

 

@2025 Daiichi Sankyo, Inc. and AstraZeneca. All rights reserved.
PP-US-8201a-2297 03/25